SGLT2 inhibitors improve cardiovascular outcomes in high-risk patients with diabetes, chronic kidney disease, or heart failure, but their effects after acute myocardial infarction are unknown.

Research findings are summarized in a new Quick Take video.

To see the full article, follow this link: [ Ссылка ]

#cardiology #clinicalmedicine #clinicaltrials #nejm

свернуть